Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Pharmacogenomics and the Treatment of Acute Myeloid Leukemia

1 Jul 2016

Abstract excerpt

Acute myeloid leukemia (AML) is a clinically and biologically heterogeneous malignancy that is primarily treated with combinations of cytarabine and anthracyclines. Although this scheme remains effective in most of the patients, variability of outcomes in patients has been partly related with their genetic variability. Several pharmacogenetic studies have analyzed the impact of polymorphisms in genes encoding...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acute Myeloid Leukemia Research
Share to Drug Transport and Resistance Mechanisms
Share to Epigenetics and DNA Methylation

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 27381050
DOI: 10.2217/pgs-2016-0055

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Pharmacogenomics and the Treatment of Acute Myeloid LeukemiaPMID 27381050Read ↗

Pharmacogenomics in acute myeloid leukemia.Semantic proximity Read ↗

SNP analyses in cytarabine metabolizing enzymes in AML patients and their impact on treatment response and patient survival: identification of CDA SNP C-451T as an independent prognostic parameter for survivalSemantic proximity Read ↗

[Research update on pharmacogenomics in acute leukemia - review].Semantic proximity Read ↗

Molecular genetic pathways as therapeutic targets in acute myeloid leukemia.Semantic proximity Read ↗

AML genomics for the clinician.Semantic proximity Read ↗

5'-nucleotidase, cytosolic II genotype, and clinical outcome in patients with acute myeloid leukemia with intermediate-risk cytogenetics.Semantic proximity Read ↗

Pharmacogenetic considerations for acute lymphoblastic leukemia therapies.Semantic proximity Read ↗

Influence of cytarabine metabolic pathway polymorphisms in acute myeloid leukemia induction treatment.Semantic proximity Read ↗

Refining AML Treatment: The Role of Genetics in Response and Resistance Evaluation to New AgentsSemantic proximity Read ↗

Application of pharmacogenetics in oncologySemantic proximity Read ↗

Current Landscape of Genome-Wide Association Studies in Acute Myeloid Leukemia: A ReviewSemantic proximity Read ↗

Cytogenetic and genetic pathways in therapy-related acute myeloid leukemiaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.